Ge Yimin, Mody Roxanne R, Olsen Randall J, Zhou Haijun, Luna Eric, Armylagos Donna, Puntachart Natu, Hendrickson Heather, Schwartz Mary R, Mody Dina R
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas; Weill Medical College of Cornell University, New York, New York.
Department of Obstetrics and Gynecology, St. Joseph's Hospital, Denver, Colorado.
J Am Soc Cytopathol. 2019 May-Jun;8(3):149-156. doi: 10.1016/j.jasc.2019.01.001. Epub 2019 Jan 14.
A considerable number of patients with high-grade cervical lesions have undergone preceding human papillomavirus (HPV) tests with negative results. In the present study, we attempted to elucidate the factors potentially contributing to the findings by testing biopsied samples from these patients.
Of the 1654 women with HPV testing and follow-up cervicovaginal biopsies from March 1, 2013 to June 30, 2014, 21 of 252 women (8.3%) with biopsy-confirmed high-grade squamous intraepithelial lesion (HSIL) or worse had had negative results from preceding high-risk (hr)HPV tests. The corresponding paraffin blocks were tested for HPV using the Cobas 4800 system, a DNA microarray against 40 HPV genotypes, and DNA sequencing.
HPV was detected in 20 (95%) of the 21 biopsies with HSIL or worse, including HPV16/18 in 4, non-16/18 hrHPV in 10, and non-hrHPV in 6. HPV59 and HPV45 were 2.2 times more frequently detected than HPV16/18 in these samples. One sample was negative for all 3 tests (5%).
Our study has demonstrated that 8.3% of women with biopsy-confirmed HSIL or worse had preceding test results that were negative for hrHPV. The vast majority of the biopsied samples had detectable HPV, primarily hrHPV genotypes (67%) with HPV59 and HPV45 predominance. This genotypic prevalence pattern was markedly different from those reported in the general population. Non-hrHPV genotypes contributed to 29% of the cases, and HPV-negative cases were rare. In addition to the limited Cobas testing panel and rare possible HPV-negative HSIL or worse, other possible contributing factors to the discrepancy include cytologic sampling, interference material, technical errors, and reduced L1 gene expression in high-grade lesions.
相当数量的高级别宫颈病变患者之前进行的人乳头瘤病毒(HPV)检测结果为阴性。在本研究中,我们试图通过检测这些患者的活检样本,阐明可能导致该结果的因素。
在2013年3月1日至2014年6月30日期间接受HPV检测并进行宫颈阴道活检随访的1654名女性中,252名活检确诊为高级别鳞状上皮内病变(HSIL)或更严重病变的女性中有21名(8.3%)之前的高危(hr)HPV检测结果为阴性。使用Cobas 4800系统、针对40种HPV基因型的DNA微阵列以及DNA测序对相应的石蜡块进行HPV检测。
21例活检确诊为HSIL或更严重病变的样本中,20例(95%)检测到HPV,其中4例为HPV16/18,10例为非16/18 hrHPV,6例为非hrHPV。在这些样本中,HPV59和HPV45的检测频率比HPV16/18高2.2倍。1个样本的所有3项检测均为阴性(5%)。
我们的研究表明,8.3%活检确诊为HSIL或更严重病变的女性之前的hrHPV检测结果为阴性。绝大多数活检样本可检测到HPV,主要为hrHPV基因型(67%),以HPV59和HPV45为主。这种基因型流行模式与一般人群中报告的模式明显不同。非hrHPV基因型占病例的29%,HPV阴性病例罕见。除了Cobas检测组有限以及罕见的可能HPV阴性的HSIL或更严重病变外,导致差异的其他可能因素包括细胞学采样、干扰物质、技术误差以及高级别病变中L1基因表达降低。